白云山:分公司获得甲苯磺酸索拉非尼化学原料药上市申请批准
Core Viewpoint - Baiyunshan (600332) has received approval from the National Medical Products Administration for the marketing application of Tofacitinib Tosylate, which is primarily used for the first-line treatment of advanced liver cancer, advanced kidney cancer, and locally advanced or metastatic thyroid cancer resistant to radioactive iodine therapy [1] Group 1 - Baiyunshan Chemical Pharmaceutical Factory has invested approximately 3.3655 million yuan in the research and development of Tofacitinib Tosylate [1] - The approval will enhance the variety of anti-tumor products offered by Baiyunshan Chemical Pharmaceutical Factory, thereby improving the company's competitiveness in the anti-tumor market [1]